Analysts have been eager to weigh in on the Healthcare sector with new ratings on Molina Healthcare (MOH – Research Report), Cara Therapeutics (CARA – Research Report) and Mineralys Therapeutics, Inc. (MLYS – Research Report).
Molina Healthcare (MOH)
In a report released today, Kevin Fischbeck from Bank of America Securities maintained a Hold rating on Molina Healthcare, with a price target of $340.00. The company’s shares closed last Monday at $292.95.
According to TipRanks.com, Fischbeck is a 3-star analyst with an average return of
Molina Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $346.00, a 15.7% upside from current levels. In a report issued on May 1, Deutsche Bank also maintained a Hold rating on the stock with a $365.00 price target.
See today’s best-performing stocks on TipRanks >>
Cara Therapeutics (CARA)
In a report released today, Jason Gerberry from Bank of America Securities reiterated a Sell rating on Cara Therapeutics, with a price target of $4.00. The company’s shares closed last Monday at $4.15, close to its 52-week low of $3.89.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cara Therapeutics with a $18.29 average price target.
Mineralys Therapeutics, Inc. (MLYS)
In a report released yesterday, Greg Harrison from Bank of America Securities reiterated a Buy rating on Mineralys Therapeutics, Inc., with a price target of $39.00. The company’s shares closed last Monday at $16.19.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of
Currently, the analyst consensus on Mineralys Therapeutics, Inc. is a Strong Buy with an average price target of $36.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MOH:
- Molina Healthcare price target lowered to $349 from $380 at TD Cowen
- Molina Healthcare price target raised to $365 from $356 at Deutsche Bank
- Molina Healthcare price target raised to $350 from $347 at Credit Suisse
- Molina Healthcare boosts FY23 adj. EPS view to at least $20.25, consensus $19.70
- Molina Healthcare reports Q1 adjusted EPS $5.81, consensus $5.12
